Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPA vs Dydrogesterone for Endometrial Hyperplasia Without Atypia
NCT03675139Phase 3Completed
- Start
- Feb 2019
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dydrogesterone in endometrial hyperplasia (EH) (2 arms). Primary endpoint: Pathological complete response (CR) rates up to 6 months. Started Feb 2019; status: completed.
02
Drugs
dydrogesterone
03
Conditions
endometrial hyperplasia (EH)
Beyond the preview
Go deeper on NCT03675139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03675139.